<DOC>
	<DOCNO>NCT00819793</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CentriMag ventricular assist system help patient experienced heart failure surgery remove cardiac bypass .</brief_summary>
	<brief_title>CentriMag Ventricular Assist System Treating Failure-to-Wean From Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>At least 18 year age Cardiac dysfunction due failuretowean cardiopulmonary bypass Subjects IABP , CPB , ECMO CPS support prior evaluation device turn , possible , purpose measure inclusion hemodynamics . However , device turn patient would harm interruption support . All subject must meet follow criterion time enrollment : Hemodynamics : 1. cardiac index ≤ 2.2 L/min/m2 2 . For patient evaluate leftsided support ( LVAD ) : PCWP ≥ 18 mmHg PADP ≥ 18 mmHg LAP ≥ 18 mmHg 3 . For patient evaluate right biventricular support : CVP ≥ 15 mmHg RAP ≥ 15 mmHg RVSWI ≤ 4.1 gm/m2/beat 4 . Enrollment without hemodynamic measurement due frequent unpredictable dysrhythmias , unacceptable cardiac function , hemodynamic instability allow . Placement intraaortic balloon pump attempt unless contraindicate All possible measure attempt correct low arterial pH , arterial blood gas abnormality , electrolyte , hypovolemia , hypervolemia , inadequate cardiac rate , dysrhythmias residual hypothermia Cardiac resuscitation use pharmacologic agent , epicardial pacing ( appropriate possible ) attempt Written , sign , date informed consent BUN &gt; 100 mg/dl Creatinine &gt; 5 mg/dl Presence investigational mechanical circulatory support device Known history liver cirrhosis portal hypertension Pulmonary infarction Stroke , TIA history either condition within last six month and/or confirm , exist neurologic deficit Active systemic infection define positive blood culture , core temperature &gt; 100.5 degree , white blood count &gt; 12,500 , treatment antimicrobial Participation clinical trial experimental treatment within 30 day prior screen previous participation present study Other serious disease ( ) limit life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cardiac Dysfunction</keyword>
	<keyword>Failure-to-wean CPB</keyword>
	<keyword>CentriMag</keyword>
	<keyword>Levitronix</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>